Low-Dose Atropine Simulator

Atropine 0.01-0.05% drops for slowing myopia progression in children.

Current Stage

—

—

Elongation reduction

—

Pupil dilation

—

Photophobia risk

—

Regimen class

—

Atropine concentration (%)0.01

Months of treatment0

Treated eye (atropine)

Untreated eye (control)

Dilated pupil margin

Muscarinic receptor block

Axial length trend line

Scroll for details

Blocking Muscarinic Receptors to Slow Scleral Remodeling

Atropine antagonizes M1-M4 receptors, placeholder mechanism sentence here.

M1–M4: Receptor subtypes (placeholder short note)
Sclera: Target tissue (placeholder short note)
~1 hr: Onset (placeholder short note)
Antimuscarinic: Class (placeholder short note)

Receptor blockade pathway

Placeholder sentence describing muscarinic receptor blockade in the retina and sclera.

Nightly Low-Concentration Drop Dosing Protocol

A single low-dose drop is instilled nightly in each eye, placeholder sentence.

0.01–0.05%: Dose range (placeholder short note)
1×/night: Frequency (placeholder short note)
Multi-year: Duration (placeholder short note)
ATOM2/LAMP: Trial (placeholder short note)

Administration schedule

Placeholder sentence describing dosing schedule and delivery method.

Flattening the Axial Length Growth Curve

Treated eyes elongate more slowly than untreated eyes, placeholder sentence.

30–60%: Reduction range (placeholder short note)
mm/year: Measure (placeholder short note)
Biometry: Method (placeholder short note)
2 years: Follow-up (placeholder short note)

Elongation rate comparison

Placeholder sentence comparing treated vs untreated axial elongation trend.

Pupil Dilation and Light Sensitivity Trade-off

Higher concentrations cause more pupil dilation and photophobia, placeholder sentence.

up to 1.5mm: Pupil increase (placeholder short note)
dose-dependent: Photophobia (placeholder short note)
minimal loss: Accommodation (placeholder short note)
Photochromic lens: Mitigation (placeholder short note)

Side effect profile

Placeholder sentence describing dilation and photophobia side effects.

Choosing a Concentration That Balances Efficacy and Comfort

Clinicians balance concentration against side effects, placeholder sentence.

0.01%: Low dose (placeholder short note)
0.025%: Mid dose (placeholder short note)
0.05%: High dose (placeholder short note)
~0.02–0.03%: Best balance (placeholder short note)

Dose-response trade-off

Placeholder sentence summarizing the concentration efficacy-safety balance.

Placeholder key-insight sentence about optimal dosing balance.